Table 5 Sensitivity and specificity of MA-LC of the later clinical trial
Performance measures | CI (95%) | |
|---|---|---|
Specificity | 94.0% | (89–97%) |
Sensitivity | 97.3% | (92–99%) |
Sensitivity per stage | ||
|---|---|---|
Stage | Number of subjects | Sensitivity |
I | 39 | 94.9% |
II | 21 | 100.0% |
III | 25 | 100.0% |
IV | 25 | 96.0% |
N/A | 1 | 100.0% |